Refine your search
Collections
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Grewal, N.
- Empaglifozin and Metformin
Abstract Views :149 |
PDF Views:127
Authors
Affiliations
1 Department of Pharmacology Punjab Institute of Medical Sciences Jalandhar, Punjab, IN
1 Department of Pharmacology Punjab Institute of Medical Sciences Jalandhar, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 5, No 1 (2016), Pagination: 1112-1113Abstract
No Abstract.- New Ray of Hope for Psychosis in Parkinsons:Pimavanserin
Abstract Views :184 |
PDF Views:135
Authors
Affiliations
1 Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, IN
1 Department of Pharmacology, Punjab Institute of Medical Sciences, Jalandhar, Punjab, IN
Source
International Journal of Medical and Dental Sciences, Vol 5, No 2 (2016), Pagination: 1347-1349Abstract
Parkinson's disease is often associated with hallucinations and psychosis. Till now typical and atypical antipsychotics (Clozapine&Quetiapine) are being used to manage these symptoms. Recently US FDA has approved a new drug Pimavanserin for the treatment of hallucination and delusion associated with parkinson's disease psychosis in a dose of 34 mg.Keywords
Hallucinations, Delusions, Psychosis, Parkinsonism, Pimavanserin.References
- Olanow CW, Schapira AHV, Obeso JA. Parkinsons disease and other movement disorders. In: Kasper, Fauci, Hauser, Longo Jameson, Loscalzo, editors. Harrisons principles of internal medicine 19th ed. New York: Mc Graw Hill Education; 2015.p.2617.
- Highlights of prescribing information. Available at: www.access data.fda.gov/drugsatfda_docs/label/2016/207318lbl.pdf. Accessed on 15.05.2016.
- Cummings J, Isaacson S, Mills R, Williams H, Chi-burris K, Corbett A, et al. Pimavanserin for patients with parkinson’s disease psychosis: a randomised, placebo- controlled phase 3 trial. The Lancet. http://dx.doi.org/10.1016/S0140-6736(13)62157-1.